[1] Galluzzi L, BravoSan Pedro JM, Vitale I, et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015[J]. Cell Death Differ, 2015, 22(1): 58-73. DOI: 10.1038/cdd.2014.137.
[2] Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an irondependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072. DOI: 10.1016/j.cell.2012.03.042.
[3] Dolma S, Lessnick SL, Hahn WC, et al. Identification of genotypeselective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells[J]. Cancer Cell, 2003, 3(3): 285-296.
[4] Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating irondependent, nonapoptotic cell death in oncogenicRASharboring cancer cells[J]. Chem Biol, 2008, 15(3): 234-245. DOI: 10.1016/j.chembiol.2008.02.010.
[5] Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation[J]. Trends Cell Biol, 2016, 26(3): 165-176. DOI: 10.1016/j.tcb.2015.10.014.
[6] Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death[J]. Nat Chem Biol, 2014, 10(1): 9-17. DOI: 10.1038/nchembio.1416.
[7] Hou W, Xie Y, Song X, et al. Autophagy promotes ferroptosis by degradation of ferritin[J]. Autophagy, 2016, 12(8): 1425-1428. DOI: 10.1080/15548627.2016.1187366.
[8] Ryu MS, Zhang D, Protchenko O, et al. PCBP1 and NCOA4 regulate erythroid iron storage and heme biosynthesis[J]. J Clin Invest, 2017, 127(5): 1786-1797. DOI: 10.1172/JCI90519.
[9] Dixon SJ, Patel DN, Welsch M, et al. Pharmacological inhibition of cystineglutamate exchange induces endoplasmic reticulum stress and ferroptosis[J]. Elife, 2014, 3: e02523. DOI: 10.7554/eLife.02523.
[10] Cramer SL, Saha A, Liu J, et al. Systemic depletion of Lcyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth[J]. Nat Med, 2017, 23(1): 120-127. DOI: 10.1038/nm.4232.
[11] Louandre C, Marcq I, Bouhlal H, et al. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells[J]. Cancer Lett, 2015, 356(2 Pt B): 971-977. DOI: 10.1016/j.canlet.2014.11.014.
[12] Cozza G, Rossetto M, BoselloTravain V, et al. Glutathione peroxidase 4catalyzed reduction of lipid hydroperoxides in membranes: the polar head of membrane phospholipids binds the enzyme and addresses the fatty acid hydroperoxide group toward the redox center[J]. Free Radic Biol Med, 2017, 112: 1-11. DOI: 10.1016/j.freeradbiomed.2017.07.010.
[13] Shintoku R, Takigawa Y, Yamada K, et al. Lipoxygenasemediated generation of lipid peroxides enhances ferroptosis induced by erastin and RSL3[J]. Cancer Sci, 2017, 108(11): 2187-2194. DOI: 10.1111/cas.13380.
[14] Woo JH, Shimoni Y, Yang WS, et al. Elucidating compound mechanism of action by network perturbation analysis[J]. Cell, 2015, 162(2): 441-451. DOI: 10.1016/j.cell.2015.05.056.
[15] Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis[J]. Nat Chem Biol, 2017, 13(1): 81-90. DOI: 10.1038/nchembio.2238.
[16] Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition[J]. Nat Chem Biol, 2017, 13(1): 91-98. DOI: 10.1038/nchembio.2239.
[17] Dixon SJ, Winter GE, Musavi LS, et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death[J]. Acs Chem Biol, 2015, 10(7): 16041609. DOI: 10.1021/acschembio.5b00245.
[18] Wenzel SE, Tyurina YY, Zhao J, et al. PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals[J]. Cell, 2017, 171(3): 628-641. e626. DOI: 10.1016/j.cell.2017.09.044.
[19] Jiang L, Kon N, Li T, et al. Ferroptosis as a p53mediated activity during tumour suppression[J]. Nature, 2015, 520(7545): 57-62. DOI: 10.1038/nature14344.
[20] Gao M, Monian P, Quadri N, et al. Glutaminolysis and transferrin regulate ferroptosis[J]. Mol Cell, 2015, 59(2): 298-308. DOI: 10.1016/j.molcel.2015.06.011.
[21] Ou Y, Wang SJ, Li D, et al. Activation of SAT1 engages polyamine metabolism with p53mediated ferroptotic responses[J]. Proc Natl Acad Sci U S A, 2016, 113(44): E6806-E6812. DOI: 10.1073/pnas.1607152113.
[22] Basuli D, Tesfay L, Deng Z, et al. Iron addiction: a novel therapeutic target in ovarian cancer[J]. Oncogene, 2017, 36(29): 4089-4099. DOI: 10.1038/onc.2017.11.
[23] Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview[J]. Cancers (Basel), 2014, 6(3): 1769-1792. DOI: 10.3390/cancers6031769.
[24] Chekhun VF, Lozovska YV, Burlaka AP, et al. Peculiarities of antioxidant system and iron metabolism in organism during development of tumor resistance to cisplatin[J]. Exp Oncol, 2014, 36(3): 196-201.
[25] Li J, He K, Liu P, et al. Iron participated in breast cancer chemoresistance by reinforcing IL6 paracrine loop[J]. Biochem Biophys Res Commun, 2016, 475(2): 154-160. DOI: 10.1016/j.bbrc.2016.05.064.
[26] Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapyresistant state of cancer cells on a lipid peroxidase pathway[J]. Nature, 2017, 547(7664): 453-457. DOI: 10.1038/nature23007.
[27] Sato M, Kusumi R, Hamashima S, et al. The ferroptosis inducer erastin irreversibly inhibits system Xc and synergizes with cisplatin to increase cisplatin′s cytotoxicity in cancer cells[J]. Sci Rep, 2018, 8(1): 968. DOI: 10.1038/s41598018192134.
[28] Sato H, Shiiya A, Kimata M, et al. Redox imbalance in cystine/glutamate transporterdeficient mice[J]. J Biol Chem, 2005, 280(45): 37423-37429. DOI: 10.1074/jbc.M506439200.
[29] Probst L, Dchert J, Schenk B, et al. Lipoxygenase inhibitors protect acute lymphoblastic leukemia cells from ferroptotic cell death[J]. Biochem Pharmacol, 2017, 140: 41-52. DOI: 10.1016/j.bcp.2017.06.112.
[30] Schott C, Graab U, Cuvelier N, et al. Oncogenic RAS mutants confer resistance of RMS13 rhabdomyosarcoma cells to oxidative stressinduced ferroptotic cell death[J]. Front Oncol, 2015, 5: 131. DOI: 10.3389/fonc.2015.00131.
[31] Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4[J]. Cell, 2014, 156(1-2): 317-331. DOI: 10.1016/j.cell.2013.12.010.
[32] Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Drugtolerant persister cancer cells are vulnerable to GPX4 inhibition[J]. Nature, 2017, 551(7679): 247-250. DOI: 10.1038/nature24297. |